ES2655492T3 - Formulaciones que comprenden cloruro de metiltioninio - Google Patents
Formulaciones que comprenden cloruro de metiltioninio Download PDFInfo
- Publication number
- ES2655492T3 ES2655492T3 ES11802119.5T ES11802119T ES2655492T3 ES 2655492 T3 ES2655492 T3 ES 2655492T3 ES 11802119 T ES11802119 T ES 11802119T ES 2655492 T3 ES2655492 T3 ES 2655492T3
- Authority
- ES
- Spain
- Prior art keywords
- mtc
- tablets
- tablet
- dissolution
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41816410P | 2010-11-30 | 2010-11-30 | |
| US418164P | 2010-11-30 | ||
| PCT/GB2011/001662 WO2012072977A2 (en) | 2010-11-30 | 2011-11-30 | Compound formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2655492T3 true ES2655492T3 (es) | 2018-02-20 |
Family
ID=45418703
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11802119.5T Active ES2655492T3 (es) | 2010-11-30 | 2011-11-30 | Formulaciones que comprenden cloruro de metiltioninio |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9192611B2 (enExample) |
| EP (1) | EP2645994B1 (enExample) |
| JP (1) | JP6093707B2 (enExample) |
| CN (1) | CN103379901B (enExample) |
| AU (1) | AU2011334679B2 (enExample) |
| CA (1) | CA2818068C (enExample) |
| ES (1) | ES2655492T3 (enExample) |
| MY (1) | MY163074A (enExample) |
| SG (2) | SG190406A1 (enExample) |
| WO (1) | WO2012072977A2 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014153444A (ja) * | 2013-02-06 | 2014-08-25 | Konica Minolta Inc | 位相差フィルム、偏光板及び液晶表示装置 |
| PL3487505T3 (pl) | 2016-07-25 | 2023-10-09 | Wista Laboratories Ltd. | Podawanie i dawkowanie diaminofenotiazyn |
| FR3104438B1 (fr) | 2019-12-12 | 2021-11-19 | Univ Bordeaux | Formulation pour le bleu de methylene et procede |
| CA3257856A1 (en) | 2022-05-31 | 2023-12-07 | Wista Laboratories Ltd. | TREATMENT OF NEURODEGENERATIVE DISORDERS USING COMPOUNDS CONTAINING METHYLTHIONINIUM (MT) |
| WO2024063700A1 (en) | 2022-09-21 | 2024-03-28 | Yin Sze Loh | Oral formulation of diaminophenothiazines and methods of making and using the same in the treatment and/or prevention of diseases |
| GB202500018D0 (en) | 2025-01-02 | 2025-02-19 | Wista Lab Ltd | Long term dosing of neurodegenerative disorders utilising methylthioninium (mt) containing compounds |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4880373A (en) | 1988-04-28 | 1989-11-14 | The Upjohn Company | Tablet press |
| JPH0840942A (ja) * | 1994-07-29 | 1996-02-13 | Kanegafuchi Chem Ind Co Ltd | 薬物放出制御製剤 |
| GB9506197D0 (en) | 1995-03-27 | 1995-05-17 | Hoffmann La Roche | Inhibition of tau-tau association. |
| GB0101049D0 (en) | 2001-01-15 | 2001-02-28 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| GB0322756D0 (en) | 2003-09-29 | 2003-10-29 | Univ Aberdeen | Methods of chemical synthesis |
| WO2006032879A2 (en) | 2004-09-23 | 2006-03-30 | Wista Laboratories Ltd. | Methods of chemical synthesis and purification of diaminophenothiazinium compounds including methylthioninium chloride (mtc) |
| JP5186212B2 (ja) * | 2004-09-23 | 2013-04-17 | ウィスタ ラボラトリーズ リミテッド | メチルチオニニウム塩化物（ｍｔｃ）などのジアミノフェノチアジニウム化合物を化学合成および精製する方法 |
| EP2039349A1 (en) * | 2004-10-19 | 2009-03-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Solid pharmaceutical composition comprising donepezil hydrochloride |
| CN101304731B (zh) * | 2005-08-24 | 2012-06-20 | 惠氏公司 | 醋酸苯卓昔芬制剂及其生产方法 |
| WO2007081367A1 (en) * | 2006-01-05 | 2007-07-19 | Teva Pharmaceutical Industries Ltd. | Dry formulations of aripiprazole |
| CN104119294B (zh) | 2006-03-29 | 2018-10-30 | 维斯塔实验室有限公司 | 3,7-二氨基-10h-吩噻嗪化合物的制备方法 |
| US20080317678A1 (en) * | 2007-06-22 | 2008-12-25 | Szymczak Christopher E | Laser Marked Dosage Forms |
| PT2954932T (pt) | 2007-10-03 | 2018-12-12 | Wista Lab Ltd | Utilização terapêutica de diaminofenotiazinas |
| CN101911081A (zh) | 2007-11-05 | 2010-12-08 | 维斯塔实验室有限公司 | 用于临床试验的体系 |
| WO2011036561A2 (en) * | 2009-09-24 | 2011-03-31 | Wis Ta Laboratories Ltd. | Process |
-
2011
- 2011-11-30 ES ES11802119.5T patent/ES2655492T3/es active Active
- 2011-11-30 SG SG2013040357A patent/SG190406A1/en unknown
- 2011-11-30 US US13/989,953 patent/US9192611B2/en active Active
- 2011-11-30 JP JP2013541414A patent/JP6093707B2/ja active Active
- 2011-11-30 SG SG10201602111VA patent/SG10201602111VA/en unknown
- 2011-11-30 EP EP11802119.5A patent/EP2645994B1/en active Active
- 2011-11-30 CN CN201180057700.9A patent/CN103379901B/zh active Active
- 2011-11-30 MY MYPI2013001934A patent/MY163074A/en unknown
- 2011-11-30 WO PCT/GB2011/001662 patent/WO2012072977A2/en not_active Ceased
- 2011-11-30 AU AU2011334679A patent/AU2011334679B2/en not_active Ceased
- 2011-11-30 CA CA2818068A patent/CA2818068C/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2011334679B2 (en) | 2016-12-15 |
| US9192611B2 (en) | 2015-11-24 |
| SG190406A1 (en) | 2013-06-28 |
| CN103379901B (zh) | 2018-04-03 |
| WO2012072977A8 (en) | 2012-09-20 |
| WO2012072977A2 (en) | 2012-06-07 |
| EP2645994B1 (en) | 2017-11-01 |
| JP6093707B2 (ja) | 2017-03-08 |
| AU2011334679A1 (en) | 2013-07-18 |
| CA2818068C (en) | 2019-06-11 |
| EP2645994A2 (en) | 2013-10-09 |
| US20130243858A1 (en) | 2013-09-19 |
| CA2818068A1 (en) | 2012-06-07 |
| SG10201602111VA (en) | 2016-04-28 |
| JP2013544272A (ja) | 2013-12-12 |
| MY163074A (en) | 2017-08-15 |
| WO2012072977A3 (en) | 2012-08-16 |
| CN103379901A (zh) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102508739B1 (ko) | Magl 억제제의 결정형 | |
| EP2842549B1 (en) | Orally disintegrating tablet and method for producing same | |
| RU2690685C2 (ru) | Фармацевтические композиции, содержащие алпелисиб | |
| US9192611B2 (en) | Formulations comprising methylthioninium chloride | |
| Abdelmonem et al. | Formulation and evaluation of baclofen-meloxicam orally disintegrating tablets (ODTs) using co-processed excipients and improvement of ODTs performance using six sigma method | |
| Alvarado et al. | In vitro biopharmaceutical equivalence of carbamazepine sodium tablets available in Lima, Peru | |
| ES2377552T3 (es) | Composiciones disueltas fácilmente y estables de candesartán cilexetilo preparadas con una granulación por vía húmeda | |
| Sutradhar | Formulation and evaluation of taste masked oral dispersible tablets of domperidone using sublimation method | |
| ES2403193T3 (es) | Composiciones que comprenden alprazolam para el tratamiento del insomnio primario y del insomnio asociado con estados de ansiedad y procedimientos para su preparación | |
| Kumar et al. | Formulation and evaluation of piroxicam fast dissolving tablets using direct compression and sublimation method | |
| Sharma et al. | A Review on Fast Dissolving Tablets | |
| Wanare et al. | Formulation and evaluation of fast dissolving tablets of azithromycin dihydrate using different super disintegrants | |
| Chimombe et al. | Orally disintegrating tablets: formulation, preparation, Evaluation and Recent Advances: A | |
| ES2863402T3 (es) | Combinación de plantas oficinales y su uso en el tratamiento y/o prevención de trastornos del sueño | |
| Rana et al. | The formulation and evaluation of mouth dissolving tablet Levocetirizine by using synthetic Superdisintegrants | |
| Paškevičiūtė et al. | OF DICLOFENAC SODIUM CAPSULES | |
| Zin et al. | Preliminary Study on the Formulation of Syariah Compliant Generic Sustained Release Gliclazide Tablet Using Xanthan Gum | |
| Seshadri et al. | Formulation and characterization of mouth dissolving tablets containing benzodiazepine | |
| HK1184386A (en) | Formulations comprising methylthioninium chloride | |
| HK1184386B (en) | Formulations comprising methylthioninium chloride | |
| ES2422657B1 (es) | Composición farmacéutica sólida de cilostazol | |
| Kumar et al. | Designing and Evaluation of Dual Release Bi-Layer of Aceclofenac Optimized By SSG and Combination Of HPMC K 4M and PVP-K30 | |
| Pujara et al. | Formulation and Evaluation of Fast Disintegrating Tablet of Ranitidine Hydrochloride Using Different Superdisintegranting Agents | |
| Ryakala et al. | Research Article Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension | |
| HK1206983B (en) | Orally disintegrating tablet and method for producing same |